Non Hodgkin Lymphoma Clinical Trial
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Summary
The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Full Description
Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.The complete response will be determined by combining IWC criteria and PET scanning.Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.
Eligibility Criteria
Inclusion Criteria:
Conformed diagnosis of follicular lymphoma, grades 1,2 or 3
No prior chemotherapy
No prior monoclonal antibody therapy
Bulky or symptomatic disease, stage II-IV
Performance status 0-2
Exclusion Criteria:
Impaired bone marrow reserve
Presence of CNS lymphoma
Serious nonmalignant disease or active infection
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Pittsburgh Pennsylvania, 15232, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.